SK bioscience, a vaccine and biotech company, has entered into a collaboration agreement with Vaxxas, a biotechnology company developing a unique vaccine patch platform technology, to develop a second-generation typhoid conjugate vaccine. SK bioscience’s SKYTyphoid vaccine will be reformulated so that it can be ‘printed’ onto the thousands of tiny micro projections covering the Vaxxas patch to be delivered directly to the abundant immune cells just under the skin surface. Th...